Volume | 25 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.49 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
3 | 25 | - | 2.4601 - 44.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:03:22 | 1 | $ 2.53 | USD |
Bio Path Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.69M | 678.80k | - | 0 | -16.08M | -23.69 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bio Path News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.41 | 7.6699 | 2.4601 | 4.18 | 17,289,435 | -2.92 | -53.97% |
1 Month | 4.14 | 7.6699 | 2.4601 | 4.17 | 4,611,592 | -1.65 | -39.86% |
3 Months | 8.60 | 9.9875 | 2.4601 | 4.31 | 1,574,042 | -6.11 | -71.05% |
6 Months | 13.174 | 14.424 | 2.4601 | 4.91 | 802,592 | -10.68 | -81.10% |
1 Year | 27.40 | 44.80 | 2.4601 | 10.66 | 1,143,836 | -24.91 | -90.91% |
3 Years | 123.00 | 172.398 | 2.4601 | 40.13 | 526,608 | -120.51 | -97.98% |
5 Years | 367.60 | 486.80 | 2.4601 | 93.20 | 527,805 | -365.11 | -99.32% |
Bio Path Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |